Abstract
The 2023-24 epidemic of Oropouche fever in the Americas and the associated ongoing outbreak in Cuba suggests a potential state shift in the epidemiology of the disease, raising questions about which vectors are driving transmission. In this study, we conduct a systematic review of vector competence experiments with Oropouche virus (OROV, Orthobunyavirus) that were published prior to the 2023-24 epidemic season. Only seven studies were published by September 2024, highlighting the chronic neglect that Oropouche virus (like many other orthobunyaviruses) has been subjected to since its discovery in 1954. Two species of midge (Culicoides paraensis and C. sonorensis) consistently demonstrate a high competence to transmit OROV, while mosquitoes (including both Aedes and Culex spp.) exhibited an infection rate consistently below ∼20%, and showed limited OROV transmission. Further research is needed to establish which vectors are involved in the ongoing outbreak in Cuba, and whether local vectors create any risk of establishment in regions with frequent travel to Latin America and the Caribbean.
Author Summary Oropouche virus has recently become a major threat to public health in Central and South America. While OROV is mainly transmitted by biting midges, some public health agencies and scientific sources note that some mosquito species may also transmit the virus. We conducted a systematic review of literature prior to the current epidemic, and identified seven studies that experimentally tested the ability of vectors to become infected with, and transmit OROV (i.e., that assessed their vector competence). These studies have consistently found that biting midges become infected at higher rates than mosquitoes, which rarely transmit the virus. It is unclear which vectors are responsible for transmitting OROV in the current outbreak. Existing published data support the observation that biting midges are likely to be significant vectors compared to mosquitoes, which are comparatively incompetent. However, increased vector surveillance and pathogen testing, and additional vector competence experiments using current OROV strains, are urgently needed.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
ENG, GDE and CJC were supported by funding to Verena (viralemergence.org) from the U.S. National Science Foundation, including NSF DBI 2021909 and NSF DBI 2213854.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data are publicly available on Figshare. A citation to the data is given in the article.
https://figshare.com/articles/dataset/Oropouche_vector_competence_data/27157029?file=49574412
